Piramal Pharma Limited Stock Price Today (NSE: PPLPHARMA)

Piramal Pharma Limited

202.371.10 (0.54%)
Market Closed

Fundamental Score

...

Piramal Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Piramal Pharma Limited share price today is 202.37, down 0.54% on NSE/BSE as of 16 September 2026. Piramal Pharma Limited (PPLPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 26.86K (Cr). The 52-week high for PPLPHARMA share price is 231.93 and the 52-week low is 132.30. The company has a Return on Equity (ROE) of -4.00% and a debt-to-equity ratio of 0.67.

Piramal Pharma Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
231.93
Low
200.10
Volume
48.9L
Change
+6.09%

Piramal Pharma Limited share price chart: 6.09% return over the past month. 52-week high ₹231.93, 52-week low ₹132.30.

Piramal Pharma Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
203.00207.96198.86202.3729.67L (Cr)
211.07211.35202.55203.4731.04L (Cr)
210.59214.45208.68211.3534.09L (Cr)
218.00218.99211.81212.4927.26L (Cr)
227.00227.75217.10218.0038.82L (Cr)
220.65231.93220.37226.62210.40L (Cr)
214.23221.80213.12219.6664.07L (Cr)
214.99217.00210.52214.2226.18L (Cr)
214.93216.90211.81214.4925.39L (Cr)
212.84217.82211.36213.7831.02L (Cr)

Piramal Pharma Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
215.00231.93198.86202.37-5.87%
196.36220.36193.03214.40+9.19%
168.68202.26166.11195.61+15.97%
172.99175.95158.10168.09-2.83%
161.87196.44157.77172.79+6.75%
140.00171.65136.26161.87+15.62%
152.62160.54132.30136.54-10.54%
152.40169.54149.76156.13+2.45%
172.75185.04148.31154.68-10.46%
187.90189.20165.12172.21-8.35%
199.76209.25184.20187.21-6.28%
191.07206.60190.52199.63+4.48%

Returns & Performance

Poor

Return on Equity (ROE)

-4.00%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

0.86%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

15.05%

Average operating profit margin over 5 years

Dividend Yield

0.08%

Annual dividend as % of current share price

Piramal Pharma Limited Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

34.86%

% shares held by company founders/management

Excellent

FII Holding

30.17%

% shares held by foreign institutional investors

Good

DII Holding

15.61%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-15.07%

Net profit growth vs same quarter last year

Good

Revenue Growth (Quarterly YoY)

17.39%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

7.03%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.67x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.32x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

679.04 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Piramal Pharma Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of PPLPHARMA across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Strong Operating Margins (15.05%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Strong Revenue Growth (17.39%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Healthy Liquidity Position (Current Ratio: 1.54)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹679.04 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 45.78%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Below-Average Return on Equity (-4.00%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (0.86%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Profit Decline Concern (-15.07%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Interest Coverage (0.32x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Piramal Pharma Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Piramal Pharma Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
8.2/100
202
₹26861.58
-4.00%
Poor
0.86%
Poor
0.7
Good
7.03%
Good
0.08%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9468
₹250888.75
85.9
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4940
₹167182.32
78.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1372
₹110828.94
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1941
₹104867.93
95.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1683
₹96839.82
26.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2101
₹96054.51
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95565.75
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2294
₹94729.81
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Piramal Pharma Limited PE Ratio History

Historical price-to-earnings ratio for PPLPHARMA — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20250.68₹172.21253.3x
FY 20240.14₹266.251901.8x
FY 20223.09₹111.9636.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Piramal Pharma Limited Dividend History

Annual cash dividends paid by PPLPHARMA — dividend yield 0.08%

Financial YearDividends Paid (₹ Cr)
FY 202514.47 Cr
FY 202367.00 Cr
FY 202250.00 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Piramal Pharma Limited Quarterly Performance

Latest quarterly metrics for PPLPHARMA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

17.39%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-15.07%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

7.03%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Piramal Pharma Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for PPLPHARMA — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
196
▲ Price above SMA 50 — Short-term bullish
SMA 200
172
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
6117K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Piramal Pharma Limited Financial Statements

Annual income statement, balance sheet and cash flow for Piramal Pharma Limited (PPLPHARMA) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Piramal Pharma Limited

Loading latest quarterly results...

About PPLPHARMA (Piramal Pharma Limited)

Piramal Pharma Ltd is a dynamic force within the global pharmaceutical landscape, carving a niche as an integrated solutions provider. From its strategic base in India, the company... orchestrates a multifaceted approach encompassing research, development, and the manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. PPLPHARMA distinguishes itself through a commitment to innovation, evident in its pursuit of novel drug delivery systems and specialized formulations designed to address unmet medical needs. This commitment extends beyond its own product portfolio, as PPLPHARMA actively engages in collaborative partnerships with pharmaceutical companies worldwide, leveraging its expertise and infrastructure to accelerate the advancement of promising therapeutic candidates. Through a relentless focus on quality and efficiency, the company is positioned as a trusted partner in the ever-evolving world of healthcare. The company's operational model is built upon a foundation of advanced manufacturing capabilities and stringent regulatory compliance. With a network of state-of-the-art facilities strategically located across various geographies, Piramal Pharma Ltd offers a seamless, end-to-end solution for pharmaceutical companies seeking to outsource key stages of their drug development and manufacturing processes. This comprehensive offering spans from early-stage research and development to late-stage commercial production, ensuring that clients receive tailored support every step of the way. PPLPHARMA emphasizes sustainability in its operations, reflecting a commitment to responsible manufacturing practices and environmental stewardship. This holistic approach, combined with its unwavering focus on customer satisfaction, solidifies the company's reputation as a reliable and ethical partner within the industry. Beyond its core contract development and manufacturing (CDMO) services, Piramal Pharma Ltd also maintains a growing portfolio of proprietary pharmaceutical products targeting specific therapeutic areas. These branded offerings are distributed through a robust global network, enabling the company to directly impact patient outcomes and improve healthcare access. PPLPHARMA’s dedication to innovation and quality is underscored by its ongoing investment in research and development, constantly exploring new avenues for therapeutic advancement and operational efficiency. The company’s forward-looking vision positions it as a key player in shaping the future of pharmaceutical manufacturing and healthcare delivery, driven by a commitment to excellence and a passion for improving lives worldwide.

Company Details

Symbol:PPLPHARMA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Nandini Ajay Piramal
Executive Chairperson
Mr. Vivek Valsaraj
CFO & Executive Director
Mr. Peter Daniel DeYoung
CEO of Piramal Global Pharma & Director

PPLPHARMA Share Price: Frequently Asked Questions

What is the current share price of Piramal Pharma Limited?

Piramal Pharma Limited (PPLPHARMA) trades at ₹202.37 on NSE and BSE. Market cap ₹26.86K (Cr). Educational data only.

What is the P/E ratio of Piramal Pharma Limited?

Piramal Pharma Limited has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Piramal Pharma Limited?

Piramal Pharma Limited has a Bull Run score of 8.2/100 based on 25+ financial parameters.

Does Piramal Pharma Limited pay dividends?

Piramal Pharma Limited has a dividend yield of 0.08%. Past dividends don't guarantee future payments.

What is the ROE of Piramal Pharma Limited?

Piramal Pharma Limited has ROE of -4.00%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Piramal Pharma Limited?

Piramal Pharma Limited has debt-to-equity of 0.67.

Is Piramal Pharma Limited a good investment?

Bull Run gives Piramal Pharma Limited a score of 8.2/100. This is not investment advice — consult a SEBI-registered advisor.